Treeline Biosciences Inc. has patented new tetrahydroisoquinoline heterobifunctional proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety potentially useful for the treatment of cancer.
Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.
Treeline Biosciences Inc. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to transcriptional enhancer factor TEF (TEAD)-targeting moiety potentially useful for the treatment of cancer.
Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.
Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) compounds comprising a cereblon (CRBN) binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL6) targeting moiety through a linker reported to be useful for the treatment of cancer.
Treeline Biosciences Inc. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) targeting moiety via linker acting as Bcl-xL degradation inducers.
Hengrui Pharmaceuticals Co. Ltd. licensed its EZH2 inhibitor, SHR-2554, to Treeline Biosciences Inc. in a deal worth more than $700 million. Treeline will be granted worldwide exclusive rights to the lymphoma drug, except for greater China, in exchange for an up-front payment of $11 million, development milestone payments of up to $45 million, and milestone payments of up to $650 million based on annual net sales once commercialization begins.
